EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes

Chia-Min Liu iD, Daniel Hsiang-Te Tsai iD, Hsiu-Ting Tung iD, Ze-Hong Lu iD, Edward Chia-Cheng Lai iD, Chan-Jung Liu

Kidney360 · 2026

DOI: 10.34067/kid.0000000981 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Kidney360, 2026. Verfasst von Chia-Min Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Nephrolithiasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Sodium-glucose cotransporter 2 inhibitors (SGLT2is) were associated with lower nephrolithiasis risk compared with dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist in patients with diabetes. Risk reduction with SGLT2i was consistent across age, glycemic control, body mass index, and renal function subgroups. Findings support potential use of SGLT2i as a preventive strategy for kidney stones in high-risk diabetic populations.

Background

Nephrolithiasis (NL) is a prevalent condition associated with diabetes mellitus (DM) and obesity, yet effective pharmacologic preventive options remain limited. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), primarily used to manage type 2 DM, have shown potential lithoprotective effects.

Methods

This retrospective multinational cohort study used electronic health records from the TriNetX database. Adults with DM initiating SGLT2i, dipeptidyl peptidase-4 inhibitors (DPP4is), or glucagon-like peptide-1 receptor agonists (GLP-1RAs) were included. Propensity score matching was conducted to balance baseline covariates, yielding 358,096 matched pairs (SGLT2i versus DPP4i) and 371,374 pairs (SGLT2i versus GLP-1RA). The primary outcome was incidence of NL.

Results

SGLT2i use was associated with a significantly lower risk of NL compared with DPP4i (1.5% versus 1.9%; hazard ratio, 0.825; 95% confidence interval, 0.795 to 0.855; P < 0.001) and GLP-1RA (1.6% versus 2.0%; hazard ratio, 0.812; 95% confidence interval, 0.784 to 0.840; P < 0.001). Subgroup analyses showed consistent protective effects across age, hemoglobin A1c, body mass index, and renal function strata, although the association was slightly attenuated in older adults, those with suboptimal glycemic control, or impaired renal function.

Conclusions

SGLT2is may reduce the risk of NL among patients with DM. Possible mechanisms include increased urinary citrate excretion, urinary alkalinization, and anti-inflammatory effects. These findings suggest that SGLT2i may reduce the risk of incident NL in diabetic populations, particularly those with additional metabolic risk factors for NL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsNephrolithiasisHumansMaleFemaleMiddle AgedRetrospective StudiesAgedGlucagon-Like Peptide-1 Receptor AgonistsAdult

Stichwörter der Autor:innen

SGLT2 inhibitorskidney stones

Substanzen

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Department of Urology, Tainan Hospital, Ministry of Health and Welfare, Tainan, Taiwan.
  • School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.
  • Department of Urology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

ORCID-Profile: Chia-Min Liu, Daniel Hsiang-Te Tsai, Hsiu-Ting Tung, Ze-Hong Lu, Edward Chia-Cheng Lai

Zitieren

APA

Liu, C. M., Tsai, D. H., Tung, H. T., Lu, Z. H., Lai, E. C., & Liu, C. J. (2026). Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes. Kidney360. https://doi.org/10.34067/kid.0000000981

Vancouver

Liu CM, Tsai DH, Tung HT, Lu ZH, Lai EC, Liu CJ. Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes. Kidney360. 2026. doi:10.34067/kid.0000000981

BibTeX
@article{Liu2026,
  author = {Liu, Chia-Min and Tsai, Daniel Hsiang-Te and Tung, Hsiu-Ting and Lu, Ze-Hong and Lai, Edward Chia-Cheng and Liu, Chan-Jung},
  title = {Sodium-Glucose Cotransporter 2 Inhibitors Prevent Nephrolithiasis in Patients with Diabetes},
  journal = {Kidney360},
  year = {2026},
  doi = {10.34067/kid.0000000981}
}
Kostenlos starten →